Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
BAYER AKTIENGESELLSCHAFT is navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is under review by 1 distinct examiner and 1 distinct art unit. SHI, GENBIN is the busiest examiner, currently handling the pending matter.
The concentration of the portfolio in 1 distinct art unit indicates a focused interaction with the USPTO. This 1 pending matter is currently the sole focus of the company's active prosecution in this technology area. For a practitioner, the involvement of a single examiner ensures that all communications remain consistent, which is critical for maintaining a unified prosecution record in the Biotechnology & Pharmaceuticals sector.
The centralized review process allows the applicant to focus resources on the specific requirements and examination style of the assigned official. This can lead to a more efficient resolution of technical rejections and a more predictable path toward allowance. By focusing on this 1 pending action, the company can ensure that its technical claims are thoroughly addressed within the specialized framework of the assigned art unit and examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHI, GENBIN | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18512098 | Larotrectinib and moderate CYP3A4 inducer | SHI, GENBIN | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18512098 | Larotrectinib and moderate CYP3A4 inducer | SHI, GENBIN | 1628 | §103§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBAYER AKTIENGESELLSCHAFT has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Genbin Shi has the most, with 1 of BAYER AKTIENGESELLSCHAFT's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
